BiotechTube

XL184 + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thyroid Cancer

Conditions

Thyroid Cancer

Trial Timeline

Jun 1, 2008 → Sep 1, 2020

NCT ID
NCT00704730

About XL184 + Placebo

XL184 + Placebo is a phase 3 stage product being developed by Exelixis for Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00704730. Target conditions include Thyroid Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00704730Phase 3Completed

Competing Products

20 competing products in Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
MBX 2109MBX BiosciencesPhase 2
47
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionMBX BiosciencesPhase 2
47
PCO371 + PlaceboChugai PharmaceuticalPhase 1
33
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
LenvatinibEisaiPre-clinical
23
LenvatinibEisaiPre-clinical
23
Lenvatinib + Placebo + LenvatinibEisaiPhase 3
77
Irofulven + capecitabineEisaiPhase 2
52
Lenvatinib + PlaceboEisaiPhase 3
77
LenvatinibEisaiApproved
85
LenvatinibEisaiPre-clinical
23
BexaroteneEisaiPhase 1
33
Lenvatinib + Lenvatinib matching placeboEisaiPhase 2
52
LenvatinibEisaiPhase 2
52
LENVATINIBEisaiPhase 2
52
E7080 capsuleEisaiPhase 2
52
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)EisaiPhase 2
52
Lenvatinib 24 mgEisaiPhase 2
52

Other Products from Exelixis

Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsuleApproved
82
cabozantinib + prednisonePhase 3
74
Cabozantinib tablets + Everolimus (Afinitor) tabletsPhase 3
74
XL092 + Atezolizumab + RegorafenibPhase 3
74
cabozantinib + mitoxantrone + prednisonePhase 3
74